Klow peptide blend: the four ingredients, and what KPV really adds

Klow is the Glow blend with one more peptide added: KPV. Sellers market it for skin and healing, with KPV pitched as the anti-inflammatory piece. No human study has tested Klow, Glow or any combination of these peptides. The name belongs to the market and not to any regulator, so the amounts and purity are whatever the seller chose, and no standard formula exists.

Klow also does worse than Glow against the October 2026 HHS policy, because the peptide that sets it apart is the one that policy does not cover by injection.

Why would anyone add KPV?

The hope is that an anti-inflammatory peptide will calm skin and speed recovery alongside the other three. Sellers present it as the ingredient that turns a skin product into something broader. Everything behind that pitch comes from gut research in cells and mice.

What does KPV actually do?

Nobody knows what it does in people. KPV is three amino acids long, the tail end of alpha-MSH (alpha-melanocyte-stimulating hormone). The study most often cited, published in Gastroenterology in 2008, found that KPV enters gut and immune cells through a transporter called PepT1 and, at nanomolar concentrations, dampened inflammatory signaling in human cell lines. Given in drinking water to mice with chemically induced colitis, it reduced inflammation. That is the basis for the anti-inflammatory claims.

What it does not show matters more. The study says nothing about people, nothing about injection and nothing about skin. The mouse work was oral and aimed at the bowel, so the leap to a skin vial crosses three gaps at once: species, route and organ. FDA says it “has not identified any human exposure data on drug products containing KPV.” The KPV benefits guide goes through the studies one at a time.

HHS’s own wording is worth reading closely. Its appendix says FDA’s safety conclusion on KPV “reflects an absence of information rather than an observed signal.” That is a fair description of what is known, and an absence of information cuts both ways: nothing bad has been recorded because very little has been recorded.

Does KPV help skin?

Nobody has shown that it does in people. The skin claims come from general inflammation models in mice and from human skin cells in a dish. FDA staff reviewed a proposed 0.1% KPV cream or gel and found no human data, and the only study in human tissue, using cadaver skin, found that KPV passes poorly through intact skin. That study tells you little about an injection, and an injection has not been studied at all. We found no published study of KPV for acne.

How is Klow different from Glow?

The only difference is one small peptide, which changes the marketing more than the evidence.

Nobody has compared the two, so there is no basis for calling either better. Each added ingredient makes a reaction harder to trace.

No combination study exists

Each ingredient has been studied separately, mostly in cells and animals. Nobody has tested the four together in a person, measured whether they interact, or checked whether they stay stable mixed in one vial. There are more possible interactions with four peptides than with three, and not one of them has been examined. Adding KPV does not add evidence for the blend. It adds a fourth injectable with no human data on that route.

Is Klow legal?

A Klow blend falls outside the interim HHS policy for three separate reasons. As of November 2, 2026, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding certain listed peptides when all ten conditions are met. Klow fails on these counts:

1. It is a blend. Condition seven requires a single active ingredient, so a multi-peptide vial is out even where each ingredient is listed.
2. GHK-Cu is not on the list. The policy names six peptides, and GHK-Cu is not among them.
3. Injected KPV is not covered. HHS limits KPV acetate to topical and oral forms. A Klow vial is sold for injection.

Any one of those would be enough. The limits of the policy apply as well: BPC-157, TB-500 and KPV remain unapproved and off the 503A bulks list, no rule has been proposed, FDA has not reviewed any compounded product, the notice says it is “not binding on HHS or the public,” HHS may revisit it, and states can be stricter. FDA’s staff proposed against listing KPV for wound healing and inflammatory conditions in July 2026, and the advisory committee voted 8 to 6 the other way, with one abstention.

GHK-Cu is on a slower track. FDA’s May 14, 2026 list says FDA intends to consult its advisory committee on GHK-Cu before the end of February 2027, and the injectable nomination was withdrawn.

Vials labeled “research use only” are not legal to use on people. Under 21 CFR 312.160 they may be shipped only for laboratory or animal tests, FDA warning letters treat that label as no defense when a product is sold for people, and the HHS policy gives them no cover. The FDA status tracker follows each ingredient.

The other three ingredients in brief

The Glow page covers these in more depth.

• GHK-Cu. The human data are cosmetic. In the one randomized study found of GHK-Cu products after laser skin resurfacing, 13 patients completed it and blinded evaluators saw no difference in redness, wrinkles or skin quality. A 2026 review calls the human literature “thin and fragmented.” A September 2026 NPR report found no published human data showing injection is safe and effective.
• BPC-157. Rat studies show faster tendon, muscle and gut healing. FDA found five small human studies, and a 2026 systematic review rated that evidence very low certainty.
• TB-500. A small fragment of thymosin beta-4. The human trials people cite, such as a 73-patient study of a gel for venous leg ulcers, used the full protein on the skin, not TB-500 by injection.

Injection versus topical

A copper peptide cream is a cosmetic, sold lawfully as long as it claims only to change appearance. A Klow vial is meant for injection, which makes it an unapproved drug. Results from creams do not transfer to injections, and KPV’s results in the mouse bowel do not transfer to skin. Under the HHS policy, KPV for skin could only be a topical single-ingredient compounded product, which is a very different thing from a four-peptide injection. That is a description of the policy and not a suggestion: no human trial supports topical KPV either.

What are the risks of Klow?

Nobody has measured them. Most of what can be said comes from the ingredients.

• Reactions nobody can trace. FDA’s report of skin and gum darkening involved a blend of just two of these peptides, and FDA could not tell which was responsible. With four, that problem gets worse.
• Immune reactions. FDA says injected peptides such as BPC-157 and TB-500 may pose a significant risk of an immune response against the peptide, with outcomes from nothing noticeable to life-threatening.
• No data on injected KPV. FDA’s safety page records no human exposure data on KPV drug products.
• No toxicity data on TB-500. FDA found none, of any kind.
• Unverified contents. Doses, ratios and purity vary by seller, and home injection brings infection and dosing risks.

The BPC-157 side effects guide includes red flags and when to call 911. No human dose has been established for the blend or for any ingredient in it, so we do not discuss amounts.

What to do instead

If the goal is better skin, the American Academy of Dermatology lists daily sun protection, moisturizer, a prescription retinoid, chemical peels, microdermabrasion, laser resurfacing, and fillers or Botox among treatments for wrinkles and sun-damaged skin. If the goal is calming a real inflammatory condition, whether that is skin or gut, that is a reason to get a diagnosis. Conditions such as ulcerative colitis are serious, and FDA lists many approved treatments for them. The skin goals guide sets out what peptides can and cannot do for skin.

Questions to ask before anyone injects you

If a clinic offers Klow, these questions will tell you a lot:

• Is this a blend? A blend is outside the HHS policy.
• Does it contain injectable KPV or GHK-Cu? Neither is covered for injection.
• Who made it, and can I see a certificate of analysis for this lot? The COA guide shows what one can and cannot prove.
• What human evidence do you have for this exact product?
• Who do I call if I react, and how is that reported to FDA?

Is Klow banned in sport?

Yes, in effect. BPC-157 is named in WADA class S0 and TB-500 in class S2, both banned at all times, so a product containing either is a doping risk regardless of its other ingredients.